13195_2019_520_MOESM5_ESM.docx (19.96 kB)
Additional file 5: of Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimerâs disease
journal contribution
posted on 2019-08-07, 04:21 authored by Michael Egan, Yuki Mukai, Tiffini Voss, James Kost, Julie Stone, Christine Furtek, Erin Mahoney, Jeffrey Cummings, Pierre Tariot, Paul Aisen, Bruno Vellas, Christopher Lines, David MichelsonTable S4. Mixed-Model Analyses for Neuropsychiatric Inventory Total Score. (DOCX 19 kb)